These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 10867111)

  • 1. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.
    Zobel AW; Nickel T; Künzel HE; Ackl N; Sonntag A; Ising M; Holsboer F
    J Psychiatr Res; 2000; 34(3):171-81. PubMed ID: 10867111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects.
    Künzel HE; Zobel AW; Nickel T; Ackl N; Uhr M; Sonntag A; Ising M; Holsboer F
    J Psychiatr Res; 2003; 37(6):525-33. PubMed ID: 14563384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats.
    Keck ME; Welt T; Wigger A; Renner U; Engelmann M; Holsboer F; Landgraf R
    Eur J Neurosci; 2001 Jan; 13(2):373-80. PubMed ID: 11168542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
    Habib KE; Weld KP; Rice KC; Pushkas J; Champoux M; Listwak S; Webster EL; Atkinson AJ; Schulkin J; Contoreggi C; Chrousos GP; McCann SM; Suomi SJ; Higley JD; Gold PW
    Proc Natl Acad Sci U S A; 2000 May; 97(11):6079-84. PubMed ID: 10823952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F; Ising M
    Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.
    Gutman DA; Owens MJ; Skelton KH; Thrivikraman KV; Nemeroff CB
    J Pharmacol Exp Ther; 2003 Feb; 304(2):874-80. PubMed ID: 12538845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a novel corticotropin-releasing-hormone receptor type I antagonist on human adrenal function.
    Willenberg HS; Bornstein SR; Hiroi N; Päth G; Goretzki PE; Scherbaum WA; Chrousos GP
    Mol Psychiatry; 2000 Mar; 5(2):137-41. PubMed ID: 10822340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm.
    Ayala AR; Pushkas J; Higley JD; Ronsaville D; Gold PW; Chrousos GP; Pacak K; Calis KA; Gerald M; Lindell S; Rice KC; Cizza G
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5729-37. PubMed ID: 15531536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRH release.
    Merali Z; Khan S; Michaud DS; Shippy SA; Anisman H
    Eur J Neurosci; 2004 Jul; 20(1):229-39. PubMed ID: 15245495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats.
    Keck ME; Welt T; Müller MB; Landgraf R; Holsboer F
    Pharmacopsychiatry; 2003 Jan; 36(1):27-31. PubMed ID: 12649771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
    Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
    J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919).
    Post A; Ohl F; Almeida OF; Binder EB; Rücker M; Welt S; Binder E; Holsboer F; Sillaber I
    Psychopharmacology (Berl); 2005 Jun; 180(1):150-8. PubMed ID: 15682302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation.
    Webster EL; Lewis DB; Torpy DJ; Zachman EK; Rice KC; Chrousos GP
    Endocrinology; 1996 Dec; 137(12):5747-50. PubMed ID: 8940412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys.
    Broadbear JH; Winger G; Rivier JE; Rice KC; Woods JH
    Neuropsychopharmacology; 2004 Jun; 29(6):1112-21. PubMed ID: 14997174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CRH1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety.
    Lancel M; Müller-Preuss P; Wigger A; Landgraf R; Holsboer F
    J Psychiatr Res; 2002; 36(4):197-208. PubMed ID: 12191624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist.
    Heinrichs SC; De Souza EB; Schulteis G; Lapsansky JL; Grigoriadis DE
    Neuropsychopharmacology; 2002 Aug; 27(2):194-202. PubMed ID: 12093593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential uses of corticotropin-releasing hormone antagonists.
    Zoumakis E; Rice KC; Gold PW; Chrousos GP
    Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety.
    Ising M; Holsboer F
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):519-28. PubMed ID: 18179304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infantile spasms: hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists.
    Baram TZ; Mitchell WG; Brunson K; Haden E
    Dev Neurosci; 1999 Nov; 21(3-5):281-9. PubMed ID: 10575251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?
    Ising M; Horstmann S; Kloiber S; Lucae S; Binder EB; Kern N; Künzel HE; Pfennig A; Uhr M; Holsboer F
    Biol Psychiatry; 2007 Jul; 62(1):47-54. PubMed ID: 17123470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.